(Circulation. 1995;92:3350-3360.)
© 1995 American Heart Association, Inc.
Articles |
From the Department of Medicine, Boston (Mass) University School of Medicine/Framingham Heart Study.
Correspondence to William B. Kannel, MD, Department of Medicine, Section of Preventive Medicine and Epidemiology, Evans Memorial Research Foundation, Boston University School of Medicine/Framingham Heart Study, Boston, MA 02118.
Abstract The epidemiological approach to investigation of cardiovascular disease was innovated in 1948 by Ancel Keys' Seven Countries Study and T.R. Dawber's Framingham Heart Study. Conducted in representative samples of the general population, these investigations provided an undistorted perception of the clinical spectrum of cardiovascular disease, its incidence and prognosis, the lifestyles and personal attributes that predispose to cardiovascular disease, and clues to pathogenesis. The many insights gained corrected numerous widely held misconceptions derived from clinical studies. It was learned, for example, that the adverse consequences of hypertension do not derive chiefly from the diastolic pressure, left ventricular hypertrophy was not an incidental compensatory phenomenon, and small amounts of proteinuria were more than orthostatic trivia. Exercise was considered dangerous for cardiovascular disease candidates; smoking, cholesterol, and a fatty diet were regarded as questionable promoters of atherosclerosis. The entities of sudden death and unrecognized myocardial infarction were not widely appreciated as prominent features of coronary disease, and the disabling and lethal nature of cardiac failure and atrial fibrillation was underestimated. It took epidemiological research to coin the term "risk factor" and dispel the notion that cardiovascular disease must have a single origin. Epidemiological investigation provided health professionals with multifactorial risk profiles to more efficiently target candidates for cardiovascular disease for preventive measures. Clinicians now look to epidemiological research to provide definitive information about possible predisposing factors for cardiovascular disease and preventive measures that are justified. As a result, clinicians are less inclined to regard usual or average values as acceptable and are more inclined to regard optimal values as "normal." Cardiovascular events are coming to be regarded as a medical failure rather than the first indication of treatment.
Key Words: epidemiology risk factors prevention
This article has been cited by other articles:
![]() |
A. Hozawa, A. R. Folsom, A. R. Sharrett, and L. E. Chambless Absolute and Attributable Risks of Cardiovascular Disease Incidence in Relation to Optimal and Borderline Risk Factors: Comparison of African American With White Subjects--Atherosclerosis Risk in Communities Study Arch Intern Med, March 26, 2007; 167(6): 573 - 579. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kerkeni, F. Addad, M. Chauffert, A. Myara, M. Ben Farhat, A. Miled, K. Maaroufi, and F. Trivin Hyperhomocysteinemia, Endothelial Nitric Oxide Synthase Polymorphism, and Risk of Coronary Artery Disease Clin. Chem., January 1, 2006; 52(1): 53 - 58. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Vasan, L. M. Sullivan, P. W.F. Wilson, C. T. Sempos, J. Sundstrom, W. B. Kannel, D. Levy, and R. B. D'Agostino Relative Importance of Borderline and Elevated Levels of Coronary Heart Disease Risk Factors Ann Intern Med, March 15, 2005; 142(6): 393 - 402. [Abstract] [Full Text] [PDF] |
||||
![]() |
M G Colombo, M G Andreassi, U Paradossi, N Botto, S Manfredi, S Masetti, G Rossi, A Clerico, and A Biagini Evidence for association of a common variant of the endothelial nitric oxide synthase gene (Glu298->Asp polymorphism) to the presence, extent, and severity of coronary artery disease Heart, June 1, 2002; 87(6): 525 - 528. [Abstract] [Full Text] [PDF] |
||||
![]() |
E.-R. Rietzschel, E. Boeykens, M. L. De Buyzere, D. A. Duprez, and D. L. Clement A Comparison Between Systolic and Diastolic Pulse Contour Analysis in the Evaluation of Arterial Stiffness Hypertension, June 1, 2001; 37 (6): e15 - e22. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. C. Swan The Framingham offspring study: A commentary J. Am. Coll. Cardiol., April 1, 2000; 35(5_Suppl_B): 13B - 17B. [PDF] |
||||
![]() |
C. Lenfant Conquering Cardiovascular Disease: Progress and Promise JAMA, December 1, 1999; 282(21): 2068 - 2070. [Full Text] [PDF] |
||||
![]() |
C. T Sempos, K. Liu, and N. D Ernst Food and nutrient exposures: what to consider when evaluating epidemiologic evidence Am. J. Clinical Nutrition, June 1, 1999; 69 (6): 1330S - 1338S. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. C. Swan The Framingham Offspring Study: a commentary J. Am. Coll. Cardiol., April 1, 1999; 33(5): 1136 - 1140. [Full Text] [PDF] |
||||
![]() |
G. Fager and O. Wiklund Cholesterol Reduction and Clinical Benefit : Are There Limits to Our Expectations? Arterioscler. Thromb. Vasc. Biol., December 1, 1997; 17(12): 3527 - 3533. [Abstract] [Full Text] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |